文摘
The dual pathway model of urothelial carcinogenesis does not fully explain grade and stage progression in patients with initial low-grade, non-muscle invasive urothelial carcinomas. Fibroblast growth factor receptor 3 (m>FGFR3m>) mutations are a hallmark of the low-grade pathway, with subsequent progression to muscle invasion occurring when m>FGFR3m> mutant tumours exhibit a homozygous m>CDKN2Am> deletion. We hypothesized that grade heterogeneity represents the morphological manifestation of molecular changes associated with disease progression.